the efficacy for type 2 Diabetes of Repaglinide taking twice or three times a day

the efficacy for type 2 Diabetes of Repaglinide taking twice or three times a day - Repaglinide:twice or three times a day

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006855

Enrollment

Registered

2011-12-15

Start date

2011-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

repaglinide taking twice a day repaglinide taking three times a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with type 2 diabetes not using insulin , SU and glinide type drugs

Exclusion criteria

Exclusion criteria: 1.type 1 diabetes 2.severe liver dysfunction 3.severe renal dysfunction

Design outcomes

Primary

Measure	Time frame
HbA1c,GA,1.5AG	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026